Share this article on:

Telmisartan as Metabolic Modulator: A New Perspective in Sports Doping?

Sanchis-Gomar, Fabian1; Lippi, Giuseppe2

The Journal of Strength & Conditioning Research: March 2012 - Volume 26 - Issue 3 - p 608-610
doi: 10.1519/JSC.0b013e31824301b6

Sanchis-Gomar, F and Lippi, G. Telmisartan as metabolic modulator: A new perspective in sports doping? J Strength Cond Res 26(3): 608–610, 2012—The World Antidoping Agency (WADA) has introduced some changes in the 2012 prohibited list. Among the leading innovations to the rules are that both 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (peroxisome proliferator–activated receptor-δ [PPAR-δ]-5' adenosine monophosphate-activated protein kinase [AMPK] agonist) and GW1516 (PPAR-δ-agonist) are no longer categorized as gene doping substances in the new 2012 prohibited list but as metabolic modulators in the class “Hormone and metabolic modulators.” This may also be valid for the angotensin II receptor blocker telmisartan. It has recently been shown that telmisartan might induce similar biochemical, biological, and metabolic changes (e.g., mitochondrial biogenesis and changes in skeletal muscle fiber type) as those reported for the former call of substances. We suspect that metabolic modulators abuse such as telmisartan might become a tangible threat in sports and should be thereby targeted as an important antidoping issue. The 2012 WADA prohibited list does not provide telmisartan for a potential doping drug, but arguments supporting the consideration to include them among “metabolic modulators” are at hand.

1Department of Physiology, Faculty of Medicine, University of Valencia, Research Foundation of the University Clinic Hospital of Valencia/INCLIVA, Valencia, Spain; and 2Clinical Chemistry and Haematology Laboratory, Department of Pathology and Laboratory Medicine, Academic Hospital of Parma, Parma, Italy

Address correspondence to Fabian Sanchis-Gomar,

© 2012 National Strength and Conditioning Association